Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 3/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | PKM | P14618 | 3/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | DHFR | P00374 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | RECQL | P46063 | 1/20 | 0.38 |
| ▸ | CA3 | P07451 | 1/20 | 0.38 |
| ▸ | CA6 | P23280 | 1/20 | 0.38 |
| ▸ | CA5A | P35218 | 1/20 | 0.38 |
| ▸ | CA9 | Q16790 | 1/20 | 0.38 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.38 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6970183 | 0.83 | SMN1; SMN2 (0.44) | MAPTSMN1; SMN2PKMMEN1HTT | |
| SCHEMBL1116575 | 0.83 | PKM (0.47) | MAPTSMN1; SMN2PKMMEN1HTT | |
| SCHEMBL12327878 | 0.81 | SMN1; SMN2 (0.44) | MAPTSMN1; SMN2PKMMEN1HTT | |
| SCHEMBL1643707 | 0.81 | CYP3A4 (0.60) | MAPTPKMMEN1HTTKMT2A | |
| SCHEMBL12895731 | 0.81 | ALDH1A1 (0.40) | SMN1; SMN2MEN1KMT2APOLBTSHR | |
| SCHEMBL19848300 | 0.79 | CYP3A4 (0.36) | MAPTSMN1; SMN2PKMMEN1HTT | |
| SCHEMBL20345719 | 0.79 | LMNA (0.53) | MAPTSMN1; SMN2HTTTSHRCYP3A4 | |
| SCHEMBL29624972 | 0.79 | LMNA (0.53) | MAPTSMN1; SMN2HTTTSHRCYP3A4 | |
| SCHEMBL21635491 | 0.79 | CYP3A4 (0.63) | MAPTSMN1; SMN2MEN1HTTKMT2A | |
| SCHEMBL21812077 | 0.79 | CYP3A4 (0.36) | MAPTSMN1; SMN2HTTTSHRCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3483149-B1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | YUHAN CORP (KR) | 2021-01-13 | — | — | EP | disclosed |
| US-10689331-B2 | IDO inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-06-23 | — | — | US | disclosed |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | YUHAN CORPORATION (KR) | 2019-08-20 | — | — | US | disclosed |
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | YUHAN CORPORATION (KR) | 2019-05-16 | — | — | US | disclosed |
| EP-3483149-A1 | BENZO[D]THIAZOLE DERIVATIVE OR SALT THEREOF, AND PHARMACEUTICAL COMPOSITION INCLUDING SAME | Yuhan Corporation (KR) | 2019-05-15 | — | — | EP | disclosed |
| US-20190002402-A1 | IDO INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2019-01-03 | — | — | US | disclosed |
| US-20180118668-A1 | NOVEL COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-05-03 | — | — | US | disclosed |
| US-20180118668-A1 | NOVEL COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2018-05-03 | — | — | US | disclosed |
| US-20170114008-A1 | NOVEL COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-04-27 | — | — | US | disclosed |
| US-20170114008-A1 | NOVEL COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF | THE CATHOLIC UNIVERSITY OF KOREA INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-04-27 | — | — | US | disclosed |
| EP-2172450-A1 | NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF | Mitsubishi Tanabe Pharma Corporation (JP) | 2010-04-07 | — | — | EP | disclosed |
| US-7297695-B2 | Pyrrolotriazine compounds as kinase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-20 | — | — | US | disclosed |
| EP-1720836-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO [D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2006-11-15 | — | — | EP | disclosed |
| US-7053104-B2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2006-05-30 | — | — | US | disclosed |
| EP-1595871-A2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2005-11-16 | — | — | EP | disclosed |
| WO-2005082859-A1 | 6-SUBSTITUTED 2,3,4,5-TETRAHYDRO-1H-BENZO[D]AZEPINES AS 5-HT2C RECEPTOR AGONISTS | ELI LILLY AND COMPANY (US) | 2005-09-09 | — | — | WO | disclosed |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | disclosed |
| US-6429207-B1 | QUINOXALINE DERIVATIVES EXHIBITING A HIGH DEGREE OF POTENCY AND SELECTIVITY FOR INDIVIDUAL METABOTROPIC GLUTAMATE RECEPTORS (MGLUR) | NPS PHARMACEUTICALS, INC. | 2002-08-06 | — | — | US | disclosed |
| EP-1196397-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2002-04-17 | — | — | EP | disclosed |
| WO-2000073283-A1 | METABOTROPIC GLUTAMATE RECEPTOR ANTAGONISTS AND THEIR USE FOR TREATING CENTRAL NERVOUS SYSTEM DISEASES | NPS PHARMACEUTICALS, INC. (US) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190142809-A1 | Benzo[D]Thiazole Derivative Or Salt Thereof, And Pharmaceutical Composition Including Same | ILK, SBDS, BDKRB1 | MAPT 2062/4885SMN1; SMN2 2540/4885PKM 129/4885 |
| US-10383859-B2 | Benzo[d]thiazole derivative or salt thereof, and pharmaceutical composition including same | ILK, SBDS, BDKRB1 | MAPT 2062/4885SMN1; SMN2 2540/4885PKM 129/4885 |
| US-20030013715-A1 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | GRM2, GRM1, GRM3 | MAPT 471/4885SMN1; SMN2 332/4885PKM 1781/4885 |
| US-20190002402-A1 | IDO INHIBITORS | IDO1, IDO2, INMT | MAPT 1988/4885SMN1; SMN2 4280/4885PKM 1894/4885 |
| US-20170114008-A1 | NOVEL COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF | NFATC1, CD14, CD209 | MAPT 2609/4885SMN1; SMN2 4832/4885PKM 4506/4885 |
| US-20180118668-A1 | NOVEL COMPOUND HAVING IMMUNE DISEASE TREATMENT EFFECT AND USE THEREOF | NFATC1, CD14, CD209 | MAPT 2609/4885SMN1; SMN2 4832/4885PKM 4506/4885 |
| US-10689331-B2 | IDO inhibitors | IDO1, IDO2, INMT | MAPT 1988/4885SMN1; SMN2 4280/4885PKM 1894/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.